Bal Pharma has reported results for the fourth quarter and year ended March 31, 2019.
The company has reported more than two fold rise in its net profit at Rs 3.57 crore for the quarter ended March 31, 2019 as compared to Rs 1.47 crore for the same quarter in the previous year. However, total income of the company decreased by 1.11% at Rs 57.03 crore for quarter under review as compared to Rs 57.67 crore for the quarter ended March 31, 2018.
On consolidated basis, the company has reported marginal rise of 73.02% in its net profit at Rs 1.09 crore for the quarter ended March 31, 2019 as compared to Rs 0.63 crore for the corresponding quarter in the FY18. Total consolidated income of the company decreased 2.83% at Rs 54.21 crore for quarter under review as compared to Rs 55.79 crore for the same quarter ended previous year.
For the year ended March 31, 2019, the company has posted a rise of 10.29% in its net profit at Rs 6.54 crore as compared to Rs 5.93 crore for the previous year. Total income of company increased 6.77% at Rs 225.79 crore for year under review as compared to Rs 211.48 crore for year ended March 31, 2018.
For the year ended March 31, 2019, on the consolidated basis, the company has posted more than five-fold rise in its net profit at Rs 1.94 crore as compared to Rs 0.37 crore for the previous year. Total income of company increased by 6.01% at Rs 225.99 crore for year under review as compared to Rs 213.17 crore for year ended March 31, 2018.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1830.20 |
Dr. Reddys Lab | 1183.00 |
Cipla | 1549.65 |
Lupin | 2094.65 |
Zydus Lifesciences | 887.70 |
View more.. |